SYNOPSIS Serum acid phosphatase (AcPase) was measured by a colorimetric method utilizing adenosine 3'-monophosphate as substrate in 389 patients. In about half the cases blood was taken shortly after a rectal examination. The upper reference limit (mean + 2SD) for 116 cases with miscellaneous illness after eliminating outliers was 4f1 International Units per litre (U/I) at 37°C, and no correlation existed between AcPase activity and age in these subjects (r = 0 040). Eight of 18 patients with untreated carcinoma confined within the prostate gland had AcPase activities below 4-1 U/1, and all of 27 cases with extension to pelvic soft tissues or to bone exceeded this value. AcPase activities above 4f1 U/l were found in 6% of cases with benign hypertrophy of the prostate, in 5% of cases with non-prostatic cancer, and in none of 22 cases with other urological illness.
An assessment of serum acid alkaline phosphatase determinations in prostatic cancer over the role of this enzyme in the diagnosis of cancer.
Recently, we introduced a new colorimetric assay for AcPase activity (Ellis, Belfield, and Goldberg, 1971) . This utilizes as substrate adenosine 3'-monophosphate which is rapidly hydrolysed by AcPase of human prostate, but poorly by AcPase of erythrocytes and other formed elements of the blood (Tsuboi and Hudson, 1953; 1955; Belfield and Goldberg, 1971) . The 37°C (U/l). Quality control samples and standards were run with each batch and it was found necessary to repeat about one batch in 10 because of the rigorous criteria laid down for acceptability of results (all controls within mean ± 2 SD and mean of all controls in batch within mean ± 1 SD). Sera were separated with the minimum possible delay and kept at 4°C, the assay being performed within 24 hours except at weekends. When sufficient serum was available, alkaline phosphatase (APase, EC 3.1.3.1.) activity was determined on the same sample by the method of Kind and King (1954) (Bodansky, 1972) supports this incidence of AcPase elevations in the two groups. Table V It is not clear why this should be so. Superiority of current diagnostic procedures is unlikely to be a factor since biopsy confirmation was lacking in the majority of cases. Improved specificity of 3'AMP for the prostatic enzyme can only have played a minor role since beta-glycerophosphate (Woodard, 1959; Bodansky, 1972) and alpha-naphthyl phosphate Babson, Read, and Phillips, 1959) are probably just as 'specific'-an adjective which in this situation is somewhat misleading, since all three substrates are hydrolysed by AcPases present in most organs and tissues (Hollander, 1971) . Similar reservations apply to the use of tartratelabile AcPase assays, introduced by Abul-Fadl and King (1949) and popularized by Fishman and Lerner (1953) as a means of estimating prostatic AcPase in serum. Claims for the superiority of this assay as a diagnostic procedure for prostatic cancer (Fishman et al, 1956) have not been substantiated (Murphy et al, 1969) , and absence of the prostate appears to make no difference to the activity of this enzyme in serum (Dow and Whitaker, 1970) .
It is clear that the distribution of cases among the various histological types will profoundly influence the incidence of raised serum AcPase levels at each stage of the disease, since well differentiated tumours are rich in the enzyme and anaplastic tumours may have greatly reduced concentrations (Mobley and Frank, 1968) . Unfortunately, we do not know the true incidence of anaplastic tumours in this series because of failure to carry out histological examinations and, even if we did, the information on this topic provided by the authors of some of the reports documented in table V are not sufficiently detailed to permit accurate assessment of the comparative incidence of various tumour types.
In view of the appallingly poor performance of AcPase assays in general laboratories (Copeland and Vanderlinde, 1972) , which must have coloured clinicians' appreciation of the test and probably influenced the data of earlier series (table V) , it seems quite possible that rigorous attention to quality control and a high standard of technical skill in an enzyme-orientated laboratory were the main factors contributing to the satisfactory results in this series.
One other factor merits consideration: the role of prostatic massage on serum AcPase levels. Six of the 13 cases without prostatic cancer but with raised serum AcPase activities had rectal examination performed within two hours of the blood being drawn or were catheterized at that time. By inducing infarction of an enlarged prostate, catheterization may lead to gross transient elevations of serum AcPase (Howard and Fraley, 1965) . Hock and Tessier (1949) reported elevation of the serum AcPase above the initial value in 17 of 20 patients undergoing rectal examination. In three out of 24 patients with benign cystic hypertrophy, significant elevation of serum AcPase activity occurred after rectal examination, probably as a consequence of rupture of cysts releasing enzyme-rich secretion into the blood (Daniel and Van Zyl, 1952) . Elevations were also reported under similar circumstances in some patients with prostatic cancer (Bonner, Homburger, and Fishman, 1954) , and as a common sequel to handling of the prostate during transvesical enucleation of the gland (Romslo, 1971 Christensen and Nielsen, 1972 In three cases the activity rose, in five cases activity fell, and in two was unchanged after rectal examination, the mean change being + 0 6 U/l. None of the five cases with normal activity (three treated and two untreated) yielded an abnormal value as a consequence of this intervention.
Elevation of serum APase activity was less frequent than that of AcPase activity, even in subjects with stage D disease. This is contrary to the experience of other authors who have reported a higher incidence of raised APase activity in patients with osseous prostatic metastases (Nesbit and Baum, 1951; Woodard, 1953 Woodard, , 1959 , although, as pointed David M. Goldberg and Graham Ellis out by Gutman (1959) , such elevations lack the specificity for the disease attributable to raised AcPase activities and are less immediately responsive to successful therapy. In view of the occurrence of raised APase activities in many subjects of the present series with no objective evidence of skeletal metastases and even in some with normal or minimally elevated AcPase levels, the assay clearly is of value as a confirmatory test. The basis of such elevations is far from clear; conceivably they could arise as a consequence of unrecognized skeletal metastases, implying that the incidence of stage D cases has been underestimated in this series and that, consequently, the occurrence of raised AcPase values in patients without such metastases has been overestimated.
The value of 41 U/l suggested as the reference limit for this AcPase assay appears to serve as a good discriminant, the overall incidence of 'falsepositive' elevations being lower than in almost all the major reports reviewed by Bodansky (1972) . Failure to find an association between serum AcPase and age is in accord with previous results (Day, Ying, Schwartz, Whitmore, and Bodansky, 1956; Ericksson, Ginsburg, Hultberg, and Ockerman, 1972) . In our hands the assay has given clinically useful results and appears to justify its inclusion in the routine investigtion of prostatic disease and even in males with non-specific 'backache'. Consideration of the curious circumstances surrounding cases 2 and 9 (table Ill) and of the fact that two of the stage D cases had been treated at a rheumatic clinic for some months before the diagnosis was made, suggests that those clinicians who ignore the value of AcPase determinations do so at the peril of some, at least, of their patients.
